Gå direkt till innehåll
Nanolyze moves to AstraZeneca’s BioVentureHub

Pressmeddelande -

Nanolyze moves to AstraZeneca’s BioVentureHub


GU Ventures share news and information about the business, its companies, and alumni companies.


Nanolyze, a Swedish company developing bioanalytical technology to study nanoparticles, has moved into the BioVentureHub at the heart of the AstraZeneca Gothenburg R&D site. 

    Nanoparticles are sub-microscopic sized units that can be powerful vehicles for delivering drugs directly into cells. Nanolyze has developed a novel technology that can be used to analyze in real time, without fluorescence, how nanoparticles interact with proteins, molecules and microscopic organisms at single particle level.

    Marianna Yanez Arteta, Associate Director in the Advanced Drug Delivery team at AstraZeneca, says, “We are constantly striving to accelerate how we can bring new drug modalities, such as oligonucleotides and mRNA, to patients safely and efficiently. Next generation drug‐delivery vehicles are dependent on bioanalytical tools capable of providing precise information about nanoparticles. It’s exciting to have Nanolyze join us in the BioVentureHub.”

    Nils Löfgren, CEO at Nanolyze, says, “The BioVentureHub is the perfect environment for us to continue our growth journey. We’re excited about the opportunity to interact with and learn from AstraZeneca scientists and colleagues in the other BioVentureHub companies. We hope to get useful feedback on our product development process so we can continue to develop user-friendly, enabling solutions that can help pharma companies get medicines to patients faster.”

    Magnus Björsne, CEO at AstraZeneca’s BioVentureHub, says, “We’re delighted that emerging life science companies, such as Nanolyze, want to join us and continue their growth journey together with us. The BioVentureHub continues to add more ingredients and flavours to the smorgasbord of collaborative and scientific innovation being catalyzed at the AstraZeneca Gothenburg site. We’re looking forward to helping Nils and his team interact, and explore value-generating opportunities, with colleagues at AstraZeneca and the other BioVentureHub companies.”

    About Nanolyze
    Nanolyze stems from research at Bio and Nanophysics at Chalmers and is currently delivering the first instruments to pilot users in Sweden and Germany. The initial research applications are within virus inhibition, extracellular vesicles, and lipid nanoparticles. The successful company growth has been nourished by being a part of the GU Ventures Incubator, which has also been housing the company until now. GU Ventures is also a co-owner together with founders and key personnel, such as ALMI Invest, STOAF, Gobia Enterrpises and a number of angels. www.nanolyze.se

    About AstraZeneca’s BioVentureHub
    AstraZeneca established the BioVentureHub in 2014 as an open innovation ecosystem to further strengthen competitiveness and dynamism in the life science industry. The BioVentureHub is based on an innovative public-private-partnership model and is located at the heart of AstraZeneca Gothenburg. It gives emerging life science companies and academic groups a unique opportunity to co-locate with and tap into the power of AstraZeneca’s world-class scientists and state of the art lab facilities and infrastructure, and with each other. www.azbioventurehub.com




    About GU Ventures AB

    GU Ventures builds businesses out of groundbreaking ideas that help shape a better tomorrow and is top-ranked by UBI Global Index as one of the world's 20 leading university-run incubators. We finance and develop new innovative business ideas with connections to the University of Gothenburg, which is one of northern Europe's largest universities. Our mission is commercialize the innovations, which leads to the utilization of research and skills, renewal of the business community, job creation and sustainable growth. Our passionate team of company builders, financial experts, IP and legal talent are dedicated supporters of our companies and ensure their successes. Since our starting point in 1995, GU Ventures has developed over 200 new business ideas of which 130 are in business today and of which 14 are listed. Our portfolio consists of 70 holdings and some projects. In the latest survey, 87% of companies match the global sustainability goals set by the UN. GU Ventures is wholly owned by the Swedish state and managed by the University of Gothenburg. Feel free to read more at: www.guventures.com.


    Relaterat material

    GU Ventures AB
    Erik Dahlbergsgatan 11A vån 2
    41126 Göteborg